Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response
Authors:
- Zoë WeaverZWZoë Weaver
- Simone DifilippantonioSDSimone Difilippantonio
- Julian CarreteroJCJulian Carretero
- Philip L. MartinPMPhilip L. Martin
- Rajaa El MeskiniRMRajaa El Meskini
- Anthony J. IacovelliAIAnthony J. Iacovelli
- Michelle GumprechtMGMichelle Gumprecht
- Alan KulagaAKAlan Kulaga
- Theresa GuerinTGTheresa Guerin
- Jerome SchlomerJSJerome Schlomer
- Maureen BaranMBMaureen Baran
- Serguei KozlovSKSerguei Kozlov
- 14 November 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (22) , 5921-5933
Abstract
Patients with lung cancer with activating mutations in the EGF receptor (EGFR) kinase, who are treated long-term with tyrosine kinase inhibitors (TKI), often develop secondary mutations in EGFR associated with resistance. Mice engineered to develop lung adenocarcinomas driven by the human EGFR T790M resistance mutation are similarly resistant to the EGFR TKI erlotinib. By tumor volume endpoint analysis, these mouse tumors respond to BIBW 2992 (an irreversible EGFR/HER2 TKI) and rapamycin combination therapy. To correlate EGFR-driven changes in the lung with response to drug treatment, we conducted an integrative analysis of global transcriptome and metabolite profiling compared with quantitative imaging and histopathology at several time points during tumor progression and treatment. Responses to single-drug treatments were temporary, whereas combination therapy elicited a sustained response. During tumor development, metabolomic signatures indicated a shift to high anabolic activity and suppression of antitumor programs with 11 metabolites consistently present in both lung tissue and blood. Combination drug treatment reversed many of the molecular changes found in tumored lung. Data integration linking cancer signaling networks with metabolic activity identified key pathways such as glutamine and glutathione metabolism that signified response to single or dual treatments. Results from combination drug treatment suggest that metabolic transcriptional control through C-MYC and SREBP, as well as ELK1, NRF1, and NRF2, depends on both EGFR and mTORC1 signaling. Our findings establish the importance of kinetic therapeutic studies in preclinical assessment and provide in vivo evidence that TKI-mediated antiproliferative effects also manifest in specific metabolic regulation. Cancer Res; 72(22); 5921–33. ©2012 AACR.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- A metabolomic approach to lung cancerLung Cancer, 2011
- Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor ModelsCancer Cell, 2011
- Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase InhibitorsPLOS ONE, 2007
- Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cellsJournal of Cell Biology, 2007
- Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination TherapyCancer Cell, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- The central role of glutathione in the pathophysiology of human diseasesArchives of Physiology and Biochemistry, 2007
- Glutathione in Cancer Biology and TherapyCritical Reviews in Clinical Laboratory Sciences, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammalsNature, 2005